NorthCrest Asset Manangement LLC Has $831,000 Holdings in Exelixis, Inc. (NASDAQ:EXEL)

NorthCrest Asset Manangement LLC lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 66.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 22,505 shares of the biotechnology company's stock after buying an additional 8,969 shares during the quarter. NorthCrest Asset Manangement LLC's holdings in Exelixis were worth $831,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Fifth Third Bancorp grew its holdings in Exelixis by 24.1% during the 1st quarter. Fifth Third Bancorp now owns 4,011 shares of the biotechnology company's stock valued at $148,000 after buying an additional 780 shares in the last quarter. USA Financial Formulas lifted its position in Exelixis by 925.8% in the first quarter. USA Financial Formulas now owns 9,930 shares of the biotechnology company's stock valued at $367,000 after purchasing an additional 8,962 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Exelixis by 230.1% in the first quarter. Assenagon Asset Management S.A. now owns 732,499 shares of the biotechnology company's stock valued at $27,044,000 after purchasing an additional 510,586 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Exelixis by 4,857.2% during the first quarter. SG Americas Securities LLC now owns 567,653 shares of the biotechnology company's stock valued at $20,958,000 after acquiring an additional 556,202 shares in the last quarter. Finally, Fiduciary Financial Group LLC bought a new position in shares of Exelixis during the first quarter valued at approximately $232,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Exelixis Trading Down 0.5%

NASDAQ EXEL traded down $0.19 during mid-day trading on Friday, reaching $41.59. 2,132,163 shares of the company's stock traded hands, compared to its average volume of 2,360,162. Exelixis, Inc. has a 1-year low of $21.36 and a 1-year high of $48.85. The company has a fifty day simple moving average of $39.69 and a 200-day simple moving average of $36.87. The company has a market cap of $11.34 billion, a price-to-earnings ratio of 23.50, a P/E/G ratio of 1.13 and a beta of 0.28.

Analysts Set New Price Targets

EXEL has been the topic of a number of recent research reports. Guggenheim set a $45.00 target price on Exelixis and gave the stock a "buy" rating in a research note on Thursday, May 15th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of Exelixis in a research note on Wednesday, May 14th. Stifel Nicolaus raised their price objective on Exelixis from $36.00 to $38.00 and gave the stock a "hold" rating in a research note on Wednesday, May 14th. Bank of America raised their price objective on Exelixis from $45.00 to $46.00 and gave the stock a "neutral" rating in a research note on Thursday, June 5th. Finally, UBS Group reaffirmed an "underperform" rating on shares of Exelixis in a research note on Thursday, April 17th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $39.76.

Insider Buying and Selling at Exelixis

In other news, EVP Jeffrey Hessekiel sold 25,000 shares of the company's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $46.18, for a total transaction of $1,154,500.00. Following the completion of the sale, the executive vice president now directly owns 693,396 shares of the company's stock, valued at $32,021,027.28. This represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Dana Aftab sold 1,508 shares of the stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $39.00, for a total value of $58,812.00. Following the completion of the sale, the executive vice president now directly owns 693,181 shares of the company's stock, valued at approximately $27,034,059. This represents a 0.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 458,113 shares of company stock worth $21,024,817 in the last 90 days. 2.82% of the stock is owned by corporate insiders.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.